Related Experiment Video
Updated: Jun 3, 2025

09:03
Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula
Published on: January 26, 2024
336
Licochalcone A-Inspired Chalcones: Synthesis and Their Antiproliferative Potential in Prostate Cancer Cells
Roxana Gonzalez Dorado1, Esveidy Isabel Oceguera Nava1, Guanglin Chen1
1Department of Chemistry & Biochemistry, California State University, Fresno, CA 93740, USA.
Molecules (Basel, Switzerland)
|January 8, 2025
Summary
Researchers developed novel licochalcone A-inspired chalcones to combat prostate cancer. Some derivatives showed potent antiproliferative activity and improved selectivity for androgen receptor-positive cancer cells.
Area of Science:
- Medicinal Chemistry
- Oncology
- Natural Products
Background:
- Prostate cancer is a major health concern requiring new therapies.
- Licochalcone A, a natural chalcone, exhibits antiproliferative effects against cancer cells.
- Previous work enhanced curcumin's potency via structural modification.
Purpose of the Study:
- To design and synthesize novel licochalcone A-inspired chalcones.
- To evaluate their antiproliferative activity against prostate cancer models.
- To explore structure-activity relationships for enhanced efficacy.
Main Methods:
- Synthesis via [3,3]-sigmatropic rearrangement and Claisen-Schmidt condensation.
- Antiproliferative activity assessed using WST-1 assay.
- Evaluation in androgen receptor (AR)-positive and AR-null prostate cancer cell lines.
Main Results:
- Licochalcone A showed modest advantage over enzalutamide in 22Rv1 cells.
- Three ester derivatives matched licochalcone A's potency in AR-positive and AR-negative cells.
- Nine derivatives exhibited enhanced selectivity for AR-positive cells (LNCaP, 22Rv1) over AR-negative cells (PC-3, DU145).
- Potency correlated with the R group on the imidazole moiety.
Conclusions:
- The phenol moiety of licochalcone A is a viable target for modification.
- Licochalcone A-inspired chalcones demonstrate potential as anti-prostate cancer agents.
- Further optimization is warranted to develop these compounds into effective therapeutics.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K

